Mucosal lesions in cutaneous lupus erythematosus successfully treated with hydroxychloroquine
Oral Science International · 2019
DOI: 10.1002/osi2.1006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Science International, 2019. Verfasst von Mayumi Kamaguchi und 4 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Cutaneous lupus erythematosus ( CLE ) is a rare, potentially disfiguring, chronic autoimmune disease with extremely variable skin and mucosal membrane manifestations. Hydroxychloroquine ( HCQ ) is an antimalarial drug that has been used in various countries to treat autoimmune diseases including CLE . HCQ was banned for a long time in Japan because of severe chloroquine retinopathy and was reapproved as a first‐line treatment for CLE in 2015. There are no case reports describing the effectiveness of HCQ for CLE with oral mucosal lesions in the dental field. We present a case of CLE whose oral lesions were successfully treated with HCQ .
Zitieren
APA
Kamaguchi, M., Iwata, H., Asaka, T., Shimizu, H., & Kitagawa, Y. (2019). Mucosal lesions in cutaneous lupus erythematosus successfully treated with hydroxychloroquine. Oral Science International. https://doi.org/10.1002/osi2.1006
Vancouver
Kamaguchi M, Iwata H, Asaka T, Shimizu H, Kitagawa Y. Mucosal lesions in cutaneous lupus erythematosus successfully treated with hydroxychloroquine. Oral Science International. 2019. doi:10.1002/osi2.1006
BibTeX
@article{Kamaguchi2019,
author = {Kamaguchi, Mayumi and Iwata, Hiroaki and Asaka, Takuya and Shimizu, Hiroshi and Kitagawa, Yoshimasa},
title = {Mucosal lesions in cutaneous lupus erythematosus successfully treated with hydroxychloroquine},
journal = {Oral Science International},
year = {2019},
doi = {10.1002/osi2.1006}
}
EUVIMED